Short answer · Medically reviewed summary · Last updated: 2026-05-08
Polycythemia Vera is a rare, chronic myeloproliferative neoplasm with an estimated prevalence of approximately 44 to 57 cases per 100,000 people globally. While incidence varies by region, it is generally estimated at 0.4 to 2.8 new cases per 100,000 individuals annually, though these figures may be conservative due to frequent underdiagnosis in early stages. Is Polycythemia Vera considered a rare disease? While Polycythemia Vera is categorized as a rare disease, it is the most common of the Philadelphia-negative myeloproliferative neoplasms.
1 people with Polycythemia Vera have shared their first-person experience on this question at DiseaseMaps.
What is the prevalence of Polycythemia Vera?
Prevalence of Polycythemia Vera: how many people are affected worldwide, differences by sex and region, with sources.
Polycythemia Vera is a rare, chronic myeloproliferative neoplasm with an estimated prevalence of approximately 44 to 57 cases per 100,000 people globally. While incidence varies by region, it is generally estimated at 0.4 to 2.8 new cases per 100,000 individuals annually, though these figures may be conservative due to frequent underdiagnosis in early stages.
Is Polycythemia Vera considered a rare disease?
While Polycythemia Vera is categorized as a rare disease, it is the most common of the Philadelphia-negative myeloproliferative neoplasms. Within the DiseaseMaps.org community, 118 people with Polycythemia Vera have shared their experiences, providing a vital real-world perspective on living with this condition that often goes beyond clinical statistics.
How does Polycythemia Vera affect different populations?
Epidemiological data for Polycythemia Vera reveals specific trends regarding age and gender distribution:
- Age of Onset: The median age at diagnosis for Polycythemia Vera is typically between 60 and 65 years; it is extremely rare in pediatric populations.
- Gender Distribution: Clinical studies suggest a slight male predominance, with a male-to-female ratio of approximately 1.2:1 to 1.5:1.
- Geographic Variation: Higher prevalence rates have been reported in North American and European populations compared to those in East Asia, though it is unclear if this reflects true genetic differences or variations in diagnostic screening.
Why is it difficult to determine the exact prevalence of Polycythemia Vera?
Accurately tracking Polycythemia Vera is challenging because many patients remain asymptomatic for years. Early-stage Polycythemia Vera is often detected incidentally during routine blood work for other health issues. Furthermore, misdiagnosis or delays in specialist referral can lead to an underestimation of the disease burden in global health registries.
Next steps
- Consult a hematologist or an oncologist specializing in myeloproliferative neoplasms (MPNs) for an accurate diagnosis.
- Track your blood counts and symptom progression to share with your care team.
- Join the DiseaseMaps.org community to connect with other patients living with Polycythemia Vera for peer support.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the guidance of a qualified healthcare provider.
References
- Orphanet: Rare Disease Database (ORPHA:756)
- NIH Genetic and Rare Diseases Information Center (GARD)
- National Organization for Rare Disorders (NORD) - Polycythemia Vera entry
- MPN Research Foundation - Clinical Data and Patient Resources
Posted Sep 16, 2017 by Patricia 2000
